Adocia to Present at the 2016 Leerink Global Healthcare Conference

**Lyon, February 04th, 2016** – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on developing innovative formulations of existing therapeutic proteins, today announced that Dr. Gérard Soula, the company’s Chairman and Chief Executive Officer, has been invited to present at the 2016 Leerink Global Healthcare Conference being held on February 10-11th, 2016 at the Waldorf Astoria Hotel in New York City.

Dr. Soula is scheduled to present on Wednesday, February 10th, 2016 at 2.15 PM EST. The presentation will take place at the C-Center Terrace.

**About ADOCIA**

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulations portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia’s clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapid-acting formulation of human insulin (HinsBet U500).

In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.

Adocia’s extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.

*Adocia aims to deliver "Innovative medicine for everyone, everywhere.”*

To learn more about Adocia, please visit us at www.ado西亚.com
For more information please contact:

**ADOCIA**
Gérard Soula  
Chairman and CEO  
[contactinvestisseurs@adocia.com](mailto:contactinvestisseurs@adocia.com)  
Tel.: +33 4 72 610 610

**ADOCIA Press Relations**
**ALIZE RP**
Caroline Carmagnol and Florence Portejoie  
[caroline@alizerp.com](mailto:caroline@alizerp.com)  
[adocia@alizerp.com](mailto:adocia@alizerp.com)  
Tel.: + 33 1 44 54 36 61

**Disclaimer**

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 'Risk Factors’ section of the Reference Document registered by the French Autorité des marchés financiers on April 30, 2015 under number R.15-032 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.